Grufity logo
Grufity logo

Latest ORBIMED ADVISORS LLC Stock Portfolio

$5.05Billion– No. of Holdings #106

Jonathan Silverstein Performance:
2026 Q1: -1.26%YTD: -1.26%2025: 19.31%
Performance for 2026 Q1 is -1.26%, and YTD is -1.26%, and 2025 is 19.31%.

About Jonathan Silverstein and 13F Hedge Fund Stock Holdings

Jonathan Silverstein is a hedge fund based in New York, NY. On 2026-05-15, the fund reported it's updated stock portfolio. In the 13F Holdings report, ORBIMED ADVISORS LLC reported an equity portfolio of $5 Billions as of 31 Mar, 2026.

The top stock holdings of ORBIMED ADVISORS LLC are EWTX, , LLY. The fund has invested 9.7% of it's portfolio in EDGEWISE THERAPEUTICS INC and 6.2% of portfolio in ENLIVEN THERAPEUTICS INC.

The fund managers got completely rid off TERNS PHARMACEUTICALS INC (TERN), APELLIS PHARMACEUTICALS INC (APLS) and THE CIGNA GROUP (CI) stocks. They significantly reduced their stock positions in ADC THERAPEUTICS SA (ADCT), KALVISTA PHARMACEUTICALS INC (KALV) and JADE BIOSCIENCES INC (AVTE). ORBIMED ADVISORS LLC opened new stock positions in ASTRAZENECA PLC, MYRIAD GENETICS INC (MYGN) and MERCK & CO INC (MRK). The fund showed a lot of confidence in some stocks as they added substantially to BICARA THERAPEUTICS INC, UNIQURE NV (QURE) and XENON PHARMACEUTICALS INC (XENE).
Jonathan Silverstein Equity Portfolio Value
Last Reported on: 15 May, 2026

Jonathan Silverstein Annual Return Estimates Vs S&P 500

Our best estimate is that ORBIMED ADVISORS LLC made a return of -1.26% in the last quarter. In trailing 12 months, it's portfolio return was 30.68%.
  • Performance
  • S&P 500

New Buys

Ticker$ Bought
astrazeneca plc132,177,000
myriad genetics inc122,875,000
merck & co inc79,800,400
avita medical inc42,516,100
guardant health inc40,199,400
syndax pharmaceuticals inc22,479,300
sutro biopharma inc19,956,500
nektar therapeutics19,786,200
New stocks bought by ORBIMED ADVISORS LLC

Additions

Ticker% Inc.
bicara therapeutics inc219
uniqure nv189
xenon pharmaceuticals inc137
ptc therapeutics inc111
mineralys therapeutics inc109
revolution medicines inc100
protagonist therapeutics inc94.01
praxis precision medicines i82.54
Additions to existing portfolio by ORBIMED ADVISORS LLC

Reductions

Ticker% Reduced
adc therapeutics sa-77.36
kalvista pharmaceuticals inc-75.31
jade biosciences inc-65.17
tectonic therapeutic inc-60.56
avalo therapeutics inc-59.98
alnylam pharmaceuticals inc-58.8
eyepoint inc-56.69
alumis inc-50.29
ORBIMED ADVISORS LLC reduced stake in above stock

Sold off

Ticker$ Sold
pmv pharmaceuticals inc-6,219,110
cytomx therapeutics inc-15,019,300
repare therapeutics inc-8,638,470
apellis pharmaceuticals inc-61,038,300
vir biotechnology inc-14,355,700
roivant sciences ltd-47,542,700
terns pharmaceuticals inc-86,993,300
rapt therapeutics inc-55,644,700
ORBIMED ADVISORS LLC got rid off the above stocks

Sector Distribution

ORBIMED ADVISORS LLC has about 61.1% of it's holdings in Healthcare sector.

  • Healthcare
  • Others
Sector%
Healthcare61.1
Others37.4
1.5

Market Cap. Distribution

ORBIMED ADVISORS LLC has about 23.6% of it's portfolio invested in the large-cap and mega-cap stocks.

  • UNALLOCATED
  • MID-CAP
  • LARGE-CAP
  • SMALL-CAP
  • MEGA-CAP
  • MICRO-CAP
Category%
UNALLOCATED37.4
MID-CAP18.1
LARGE-CAP16.8
SMALL-CAP15.1
MEGA-CAP6.8
MICRO-CAP5

Stocks belong to which Index?

About 47.9% of the stocks held by ORBIMED ADVISORS LLC either belong to S&P 500 or RUSSELL 2000 index.

  • Others
  • RUSSELL 2000
  • S&P 500
Index%
Others52.1
RUSSELL 200027.6
S&P 50020.3
Top 5 Winners (%)%
enliven therapeutics inc
154.6 %
alumis inc
94.1 %
q32 bio inc
93.4 %
CRVS
corvus pharmaceuticals inc
90.0 %
STTK
shattuck labs inc
76.2 %
Top 5 Winners ($)$
enliven therapeutics inc
189.4 M
EWTX
edgewise therapeutics inc
103.7 M
CRVS
corvus pharmaceuticals inc
49.7 M
cg oncology inc
32.2 M
STTK
shattuck labs inc
17.5 M
Top 5 Losers (%)%
upstream bio inc
-66.8 %
KROS
keros therapeutics inc
-44.5 %
CYBN
cybin inc
-41.3 %
lexeo therapeutics inc
-36.7 %
BSX
boston scientific corp
-33.9 %
Top 5 Losers ($)$
upstream bio inc
-103.3 M
BSX
boston scientific corp
-78.3 M
LLY
eli lilly & co
-41.7 M
SBTX
ars pharmaceuticals inc
-30.0 M
structure therapeutics inc
-28.2 M

Jonathan Silverstein Holdings Map

This heatmap illustrates the top 50 positions within the fund's portfolio.

Current Stock Holdings of Jonathan Silverstein

ORBIMED ADVISORS LLC has 106 stocks in it's portfolio. About 38.9% of the portfolio is in top 10 stocks. proved to be the most loss making stock for the portfolio. was the most profitable stock for ORBIMED ADVISORS LLC last quarter.

Last Reported on: 15 May, 2026
TickerNamesorted ascending% PortfolioShares Held$ ValueType% ChangeOptions